Skip to main content
Premium Trial:

Request an Annual Quote

CRISPR and mRNA Together

In addition to fueling some COVID-19 vaccines, mRNA could also be used to deliver CRISPR therapies, Time magazine writes.

It notes that in June, researchers led by the University College London's Julian Gillmore reported in the New England Journal of Medicine on their test of Intellia Therapeutics and Regeneron's CRISPR-based drug to treat transthyretin amyloidosis. The small study, as GenomeWeb reported, found treatment led to a reduction in serum TTR protein levels —TTR accumulates in transthyretin amyloidosis in nerves and the heart.

Time adds that the study's use of mRNA to deliver CRISPR machinery highlights how it could be used beyond vaccines, as the approach could be adapted beyond transthyretin amyloidosis for other diseases and conditions. "To imagine using [CRISPR] as a therapy for people, you need to figure out how to get these editing tools into the cells you're trying to fix. That's where messenger RNA comes in," Daniel Anderson from MIT and CRISPR Therapeutics, who was not involved in the research, tells Time.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.